Skip Navigation


JAC Advance Access originally published online on August 10, 2006
Journal of Antimicrobial Chemotherapy 2006 58(4):789-793; doi:10.1093/jac/dkl338
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/4/789    most recent
dkl338v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daeschlein, G.
Right arrow Articles by Kekulé, A.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daeschlein, G.
Right arrow Articles by Kekulé, A.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

In vitro activity of linezolid against clinical isolates of Fusobacterium spp.

G. Daeschlein1, C. Hoehne1, O. Assadian2,*, F. Daxboeck2, C. Meinl2, A. Kramer3 and A.S. Kekulé1

1 Institute for Medical Microbiology, Martin-Luther-University Halle-Wittenberg Halle/Saale, Germany 2 Department for Hygiene and Medical Microbiology, Medical University of Vienna Vienna, Austria 3 Institute for Hygiene and Environmental Medicine, Ernst-Moritz-Arndt University Greifswald, Germany

Received 26 May 2006; returned 6 July 2006; revised 8 July 2006; accepted 26 July 2006

*Corresponding author. Tel: +43-1-40400-1904; Fax: +43-1-40400-1907; E-mail: ojan.assadian{at}meduniwien.ac.at

Objectives: Although most susceptibility studies for linezolid have investigated aerobic bacteria, only a few have investigated anaerobe isolates. The aim of the present study was to determine the antibacterial activity of linezolid against a larger sample of clinical isolates of Fusobacterium spp. and to report on the detailed susceptibility, stratified by species.

Methods: The in vitro susceptibility of 80 clinical isolates of Fusobacterium (Fusobacterium necrophorum, n = 34; Fusobacterium nucleatum, n = 20; Fusobacterium varium, n = 18; Fusobacterium mortiferum; n = 8) was tested and compared with the activity of the older compounds amoxicillin and amoxicillin/clavulanic acid.

Results: The MIC of linezolid ranged from 0.016 to 1.0 mg/L, with the MIC90 being 0.5 mg/L. The highest MIC obtained for linezolid (1.0 mg/L) was measured for an F. varium isolate. The MIC90 for both, amoxicillin (range: 0.016–0.75 mg/L) and amoxicillin/clavulanic acid (range: 0.047–0.75 mg/L), was 0.5 mg/L. Overall, no resistant strains were found in the study.

Conclusions: Compared with amoxicillin and amoxicillin/clavulanic acid, linezolid was less active against F. necrophorum (MIC90 0.25 mg/L) and F. nucleatum (MIC90 0.25 mg/L), equally active against F. varium (MIC90 0.75 mg/L) and slightly more active against F. mortiferum (MIC90 0.19 mg/L).

Keywords: anaerobic bacteria , susceptibility , MIC , resistance , amoxicillin , amoxicillin/clavulanic acid


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.